肌球蛋白轻链激酶在非酒精性脂肪性肝病发病机制中的作用  

Research progress in role of myosin light chain kinase in pathogenesis of nonalcoholic fatty liver disease

作　　者：李春苗[1] 庄丽维[1] 

机构地区：[1]哈尔滨医科大学附属第四医院,哈尔滨150000

出　　处：《临床肝胆病杂志》2015年第7期1156-1159,共4页Journal of Clinical Hepatology

基　　金：黑龙江省自然科学基金(D201139)

摘　　要：肌球蛋白轻链激酶(MLCK)是参与肠黏膜机械屏障功能的关键酶,在非酒精性脂肪性肝病(NAFLD)发病机制中发挥重要作用。介绍了影响NAFLD的"二次打击学说",肠道来源的内毒素在其发病机制中起着主要作用,叙述了内毒素、MLCK与NAFLD三者之间的联系,以及应用肌球蛋白轻链激酶抑制剂ML-7对肠道屏障的影响,应用ML-7可能对NAFLD的形成和进展起到抑制和延缓的作用,进而为早期预防NAFLD提供了新的临床思路。Myosin light chain kinase（ MLCK） is a key enzyme involved in intestinal mucosal mechanical barrier and plays an important role in the pathogenesis of nonalcoholic fatty liver disease（ NAFLD）. This article describes the ＂ two- hit theory＂ for NAFLD and gut- derived endotoxin which plays a major role in the pathogenesis of NAFLD,the relationship between endotoxin,MLCK,and NAFLD,and the impact of MLCK inhibitor ML- 7 on the intestinal barrier. MLCK inhibitor ML- 7 may hinder and delay the development and progression of NAFLD,providing a novel clinical idea for the early prevention of NAFLD.

关 键 词：脂肪肝 肌球蛋白轻链激酶 病理过程 综述 

分 类 号：R575.5[医药卫生—消化系统]